Contribution of mutations in ATM to breast cancer development in the Czech population

Oncology Reports

Volumn 19, Issue 6, 2008, Pages 1505-1510

  Soukupova, Jana ^a   Dundr, Pavel ^a   Kliebl, Zdenek ^a   Pohlreich, Petr ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Ataxia telangiectasia; ATM gene; Breast cancer; Protein truncation test; Susceptibility genes

Indexed keywords

ADENINE; ATM PROTEIN; GUANINE; THYMINE; CELL CYCLE PROTEIN; DNA BINDING PROTEIN; PROTEIN SERINE THREONINE KINASE; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; BREAST CANCER; CANCER GROWTH; CONTROLLED STUDY; CZECH REPUBLIC; DNA SEQUENCE; DNA SPLICING; FAMILY HISTORY; FEMALE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC CODE; GENETIC VARIABILITY; HETEROZYGOTE; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; INHERITANCE; MISSENSE MUTATION; NUCLEIC ACID BASE SUBSTITUTION; NUCLEOTIDE SEQUENCE; POPULATION RESEARCH; PRIORITY JOURNAL; PROMOTER REGION; SEQUENCE ANALYSIS; ADULT; ALTERNATIVE RNA SPLICING; BREAST TUMOR; CZECHOSLOVAKIA; DNA METHYLATION; ENZYME IMMUNOASSAY; GENETIC PREDISPOSITION; GENETICS; HETEROZYGOSITY LOSS; METABOLISM; MIDDLE AGED; MUTATION; ONSET AGE; PATHOLOGY;

ADULT; AGE OF ONSET; ALTERNATIVE SPLICING; BREAST NEOPLASMS; CELL CYCLE PROTEINS; CZECHOSLOVAKIA; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; DNA-BINDING PROTEINS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HUMANS; IMMUNOENZYME TECHNIQUES; LOSS OF HETEROZYGOSITY; MIDDLE AGED; MUTATION; PROMOTER REGIONS (GENETICS); PROTEIN-SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEINS;

EID: 48849108194     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Nathanson KL, Wooster R and Weber BL: Breast cancer genetics: what we know and what we need. Nat Med 7: 552-556, 2001.
2. Prokopcova J, Kleibl Z, Banwell CM and Pohlreich P: The role of ATM in breast cancer development. Breast Cancer Res Treat 104: 121-128, 2006.
3. Bakkenist CJ and Kastan MB: DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 421: 499-506, 2003.
4. Swift M, Morrell D, Cromartie E, Chamberlin AR, Skolnick MH and Bishop DT: The incidence and gene frequency of ataxia-telangiectasia in the United States. Am J Hum Genet 39: 573-583, 1986.
5. McKinnon PJ: ATM and ataxia-telangiectasia. EMBO Rep 5: 772-776, 2004.
6. Swift M, MorTell D, Massey RB, and Chase CL: Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med 325: 1831-1836, 1991.
7. Olsen JH, Hahnemann JM, Borresen-Dale AL, Brondum-Nielsen K, Hammarstrom L, Kleinerman R, Kaariainen H, Lonnqvist T, Sankila R, Seersholm N, Tretli S, Yuen J, Boice JD Jr and Tucker M: Cancer in patients with ataxia-telangiectasia and in their relatives in the Nordic countries. J Natl Cancer Inst 93: 121-127, 2001.
8. FitzGerald MG, Bean JM, Hegde SR, Unsal H, MacDonald DJ, Harkin DP, Finkelstein DM, Isselbacher KJ and Haber DA: Heterozygous ATM mutations do not contribute to early onset of breast cancer. Nat Genet 15: 307-310, 1997.
9. Ramsay J, Birrell G and Lavin M: Testing for mutations of the ataxia-telangiectasia gene in radiosensitive breast cancer patients. Radiother Oncol 47: 125-128, 1998.
10. Dork T, Bendix R, Bremer M, Rades D, Klopper K, Nicke M, Skawran B, Hector A, Yamini P, Steinmann D, Weise S, Stuhrmann M and Karstens JH: Spectrum of ATM gene mutations in a hospital-based series of unselected breast cancer patients. Cancer Res 61: 7608-7615, 2001.
11. Renwick A, Thompson D, Seal S, Kelly P, Chagtai T, Ahmed M, North B, Jayatilake H, Barfoot R, Spanova K, McGuffog L, Evans DG, Eccles D, Easton DF, Stratton MR and Rahman N: ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet 38: 873-875, 2006.
12. Pohlreich P, Zikan M, Stribrna J, Kleibl Z, Janatova M, Kotlas J, Zidovska J, Novotny J, Petruzelka L, Szabo C and Matous B: High proportion of recurrent germline mutations in the BRCA1 gene in breast and ovarian cancer patients from the Prague area. Breast Cancer Res 7: R728-R736, 2005.
13. Chomczynski P and Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 162: 156-159, 1987.
14. Telatar M, Teraoka S, Wang Z, Chun HH, Liang T, Castellvi-Bel S, Udar N, Borresen-Dale AL, Chessa L, Bernatowska-Matuszikiewicz E, Porras O, Watanabe M, Junker A, Concannon P and Gatti RA: Ataxia-telangiectasia: identification and detection of founder-effect mutations in the ATM gene in ethnic populations. Am J Hum Genet 62: 86-97, 1998.
15. Den Dunnen JT and Paalman MH: Standardizing mutation nomenclature: why bother? Hum Mutat 22: 181-182, 2003.
16. Sandoval N, Platzer M, Rosenthal A, Dork T, Bendix R, Skawran B, Stuhrmann M, Wegner RD, Sperling K, Banin S, Shiloh Y, Baumer A, Bernthaler U, Sennefelder H, Brohm M, Weber BH and Schindler D: Characterization of ATM gene mutations in 66 ataxia telangiectasia families. Hum Mol Genet 8: 69-79, 1999.
17. Broeks A, Urbanus JH, de Knijff P, Devilee P, Nicke M, Klopper K, Dork T, Floore AN and van't Veer LJ: IVS10-6T>G, an ancient ATM germline mutation linked with breast cancer. Hum Mutat 21: 521-528, 2003.
18. Renwick A, Thompson D, Seal S, Kelly P, Chagtai T, Ahmed M, North B, Jayatilake H, Barfoot R, Spanova K, McGuffog L, Evans DG, Eccles D, Easton DF, Stratton MR and Rahman N: ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles, Nat Genet 38: 873-875, 2006.
19. Thorstenson YR, Roxas A, Kroiss R, Jenkins MA, Yu KM, Bachrich T, Muhr D, Wayne TL, Chu G, Davis RW, Wagner TM and Oefner PJ: Contributions of ATM mutations to familial breast and ovarian cancer. Cancer Res 63: 3325-3333, 2003.
20. Szabo CI, Schutte M, Broeks A, Houwing-Duistermaat JJ, Thorstenson YR, Durocher F, Oldenburg RA, Wasielewski M, Odefrey F, Thompson D, Floore AN, Kraan J, Klijn JG, van den Ouweland AM, Wagner TM, Devilee P, Simard J, van't Veer LJ, Goldgar DE and Meijers-Heijboer H: Are ATM mutations 7271T→G and IVS10-6T→G really high-risk breast cancer-susceptibility alleles? Cancer Res 64: 840-843, 2004.
21. Bernstein JL, Teraoka S, Southey MC, Jenkins MA, Andrulis IL, Knight JA, John EM, Lapinski R, Wolitzer AL, Whittemore AS, West D, Seminara D, Olson ER, Spurdle AB, Chenevix-Trench G, Giles GG, Hopper JL and Concannon P: Population-based estimates of breast cancer risks associated with ATM gene variants c.7271T>G and c.1066-6T>G (IVS10-6T>G) from the Breast Cancer Family Registry. Hum Mutat 27: 1122-1128, 2006.
22. Bay JO, Uhrhammer N, Pernin D, Presneau N, Tchirkov A, Vuillaume M, Laplace V, Grancho M, Verrelle P, Hall J and Bignon YJ: High incidence of cancer in a family segregating a mutation of the ATM gene: possible role of ATM heterozygosity in cancer. Hum Mutat 14: 485-492, 1999.
23. Lu S, Shen K, Wang Y, Santner SJ, Chen J, Brooks SC and Wang YA: Atm-haploinsufficiency enhances susceptibility to carcinogen-induced mammary tumors. Carcinogenesis 27: 848-855, 2006.
24. Rio PG, Pernin D, Bay JO, Albuisson E, Kwiatkowski F, De Latour M, Bernard-Gallon DJ and Bignon YJ: Loss of heterozygosity of BRCA1, BRCA2 and ATM genes in sporadic invasive ductal breast carcinoma. Int J Oncol 13: 849-853, 1998.